Similar cancer detection rates seen for transperineal versus transrectal biopsy, but reduction in infections seen for transperineal<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Sept. 30, 2024 (HealthDay News) — For patients with suspicion for prostate cancer, transperineal biopsy has similar cancer detection rates as transrectal biopsy but a significantly lower risk for infection, according to a research letter published online Sept. 19 in JAMA Oncology<\/em>.<\/p>\n Jim C. Hu, M.D., M.P.H., from the New York Presbyterian Weill Cornell Medicine Hospital in New York City, and colleagues randomly assigned patients with suspicion for prostate cancer to clinic-based transperineal biopsy (without antibiotic prophylaxis) or transrectal biopsy (with targeted prophylaxis). A total of 875 patients were randomly assigned from February 2021 through March 2024; 372 and 370 underwent biopsy in the transperineal and transrectal groups, respectively.<\/p>\n The researchers found no infections in the transperineal group versus six infections in the transrectal group in an intent-to-treat analysis (difference, \u00e2\u0088\u00921.6 percent). Low and similar rates of other complications were seen. Overall, 55 and 52 percent of patients in the transperineal and transrectal groups, respectively, had high-grade cancer (difference, 2.9 percent).<\/p>\n “Transperineal biopsy significantly lowers the risk of infectious complications versus transrectal biopsy,” the authors write. “Transperineal biopsy should be the standard of care for prostate biopsy.”<\/p>\n One author disclosed financial ties to Perineologic and KOELIS.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n